A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Table of Contents Edwards Lifesciences Corporation is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence, and meaningful partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Edwards Lifesciences has been a leader in our field for over six decades. Since our founder, Miles “Lowell” Edwards, first dreamed of using engineering to address diseases of the human heart, we have steadily built a company on the premise of imagining, building, and realizing a better future for patients. Our innovative work encompasses both surgical and transcatheter therapies.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 6.1B | 6.1B | 5.4B | 5.0B | 5.4B | 5.2B |
| Net Income | 1.1B | 1.1B | 4.2B | 1.4B | 1.5B | 1.5B |
| EPS | $1.83 | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
| Free Cash Flow | 1.3B | 1.3B | 290M | 643M | 974M | 1.4B |
| ROIC | 13.0% | 15.6% | 39.4% | 20.4% | 28.5% | 29.5% |
| Gross Margin | 78.0% | 78.0% | 79.5% | 80.5% | 79.9% | 76.1% |
| Debt/Equity | 0.07 | 0.07 | 0.07 | 0.10 | 0.12 | 0.12 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 1.3B | 1.3B | 1.4B | 1.3B | 1.7B | 1.7B |
| Operating Margin | 20.8% | 20.8% | 25.3% | 26.1% | 32.5% | 32.3% |
| ROE | 10.4% | 10.6% | 41.8% | 21.1% | 26.2% | 25.8% |
| Shares Outstanding | 587M | 587M | 599M | 610M | 624M | 632M |
Edwards Lifesciences Corp passes 8 of 9 quality checks, indicating strong fundamentals.
Edwards Lifesciences Corp trades at 42.7x trailing earnings, compared to its 15-year median P/E of 43.5x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 34.3x vs a median of 46.8x. The company's 5-year average ROIC is 26.7% with a gross margin of 78.8%. Total shareholder yield (buybacks) is 1.9%. At current prices, the estimated annualized return to fair value is -1.5%.
Edwards Lifesciences Corp (EW) has a current P/E ratio of 42.7, compared to its historical median P/E of 43.5. The stock is currently considered Fair based on its historical valuation range.
Edwards Lifesciences Corp (EW) has a 5-year average return on invested capital (ROIC) of 26.7%. This indicates strong capital allocation and a potential competitive advantage.
Edwards Lifesciences Corp (EW) has a market capitalization of $45.8B. It is classified as a large-cap stock.
Edwards Lifesciences Corp (EW) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 1.95%.
Based on historical P/E analysis, Edwards Lifesciences Corp (EW) appears fair. The current P/E of 42.7 is 2% below its historical median of 43.5. The estimated fair value CAGR (P/E method) is 20.7%.
Edwards Lifesciences Corp (EW) operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry, within the Healthcare sector.
Edwards Lifesciences Corp (EW) reported annual revenue of $6.1 billion in its most recent fiscal year, based on SEC EDGAR filings.
Edwards Lifesciences Corp (EW) has a net profit margin of 17.7%. This is a healthy margin.
Edwards Lifesciences Corp (EW) generated $1.3 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Edwards Lifesciences Corp (EW) has a debt-to-equity ratio of 0.07. This indicates a conservatively financed balance sheet.
Edwards Lifesciences Corp (EW) reported earnings per share (EPS) of $1.83 in its most recent fiscal year.
Edwards Lifesciences Corp (EW) has a return on equity (ROE) of 10.6%. This indicates moderate shareholder returns.
Edwards Lifesciences Corp (EW) has a 5-year average gross margin of 78.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 18 years of financial data for Edwards Lifesciences Corp (EW), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Edwards Lifesciences Corp (EW) has a book value per share of $17.62, based on its most recent annual SEC filing.